Sanofi to buy Ablynx for €3.9bn, leaving Novo Nordisk in the cold
Sanofi is set to acquire its antibody-fragment tech partner Ablynx for €3.9bn ($4.8bn).
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Sanofi is set to acquire its antibody-fragment tech partner Ablynx for €3.9bn ($4.8bn).